These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21878363)

  • 1. The serotonergic system in Parkinson's disease.
    Huot P; Fox SH; Brotchie JM
    Prog Neurobiol; 2011 Oct; 95(2):163-212. PubMed ID: 21878363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
    Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
    Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonergic neurotransmission in early Parkinson's disease: a pilot study to assess implications for depression in this disorder.
    Beucke JC; Uhl I; Plotkin M; Winter C; Assion HJ; Endrass T; Amthauer H; Kupsch A; Juckel G
    World J Biol Psychiatry; 2010 Sep; 11(6):781-7. PubMed ID: 20586535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The serotonergic system in motor and non-motor manifestations of Parkinson's disease.
    Huot P; Fox SH
    Exp Brain Res; 2013 Oct; 230(4):463-76. PubMed ID: 23811734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin and Parkinson's disease: On movement, mood, and madness.
    Fox SH; Chuang R; Brotchie JM
    Mov Disord; 2009 Jul; 24(9):1255-66. PubMed ID: 19412960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
    Huot P; Fox SH; Newman-Tancredi A; Brotchie JM
    J Pharmacol Exp Ther; 2011 Oct; 339(1):2-8. PubMed ID: 21784889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
    Monti JM; Jantos H
    Prog Brain Res; 2008; 172():625-46. PubMed ID: 18772053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
    Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
    Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery.
    Rylander D
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S126-8. PubMed ID: 22166409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease.
    Navailles S; Bioulac B; Gross C; De Deurwaerdère P
    Neurobiol Dis; 2011 Feb; 41(2):585-90. PubMed ID: 21092759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight into the therapeutic role of the serotonergic system in Parkinson's disease.
    Ohno Y; Shimizu S; Tokudome K; Kunisawa N; Sasa M
    Prog Neurobiol; 2015 Nov; 134():104-21. PubMed ID: 26455457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
    Muñoz A; Carlsson T; Tronci E; Kirik D; Björklund A; Carta M
    Exp Neurol; 2009 Sep; 219(1):298-307. PubMed ID: 19500572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
    Lane EL; Brundin P; Cenci MA
    Neurobiol Dis; 2009 Jul; 35(1):42-51. PubMed ID: 19361557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.
    Di Matteo V; Di Giovanni G; Pierucci M; Esposito E
    Prog Brain Res; 2008; 172():7-44. PubMed ID: 18772026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin/dopamine interaction in learning.
    Olvera-Cortés ME; Anguiano-Rodríguez P; López-Vázquez MA; Alfaro JM
    Prog Brain Res; 2008; 172():567-602. PubMed ID: 18772051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
    Dupre KB; Eskow KL; Negron G; Bishop C
    Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.